FDA asks Discovery Labs for more info on Surfaxin

Discovery Laboratories said Monday the Food and Drug Administration wants even more information for the company's new drug application on Surfaxin, designed to prevent respiratory distress in premature infants. This is the FDA's second request for more information from Discovery. If approved, Surfaxin would be Discovery's first product to reach market.

- read this story from the Philadelphia Business Journal for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.